Swine Vaccines Market Size & Growth Forecast 2027–2036, By Segments (Product, Route of Administration, Disease Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Swine Vaccines Market size was worth USD 1.9 billion in 2026 and is poised to grow at a 5.23% CAGR between 2027 and 2036, reaching USD 3.16 billion by 2036. The industry revenue for 2027 is assessed at USD 1.98 billion.
Get more details on this report
Request Free Sample ReportSwine Vaccines Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 40.77% market share in 2026, supported by established commercial swine production, preventive veterinary practices, and routine vaccine use across large-scale farming operations.
- Asia Pacific is projected to grow at a 6.33% CAGR as expanding pork production systems increasingly adopt preventive vaccination to improve herd health, reduce disease losses, and enhance farm productivity.
Segment Momentum
- Inactivated (Killed) vaccines accounted for 54.63% of the market in 2026 due to their established role in routine herd health programs, dependable handling, and broad acceptance across commercial swine production systems.
- Oral administration is expanding fastest because it enables more practical herd-level vaccination, reduces handling intensity, and supports efficient large-scale vaccine deployment where labor efficiency and ease of administration are priorities.
Market Expansion Drivers
- Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption.
- Growing global pork consumption driving herd health management and preventive vaccination demand.
- Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency.
Leading Market Participants
- Major companies in the swine vaccines market include Zoetis Inc. (United States), Merck & Co., Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (United States), Ceva Santé Animale (France), HIPRA, S.A. (Spain), Virbac S.A. (France), Phibro Animal Health Corporation (United States), Biogénesis Bagó S.A. (Argentina), Indian Immunologicals Ltd. (India).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.9 billion
- 2027 Estimated Market Size: USD 1.98 billion.
- Projected Market Size: USD 3.16 billion by 2036
- Growth Forecast: 5.23% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Inactivated (Killed) (Product) | Injectables (Route of Administration) | PRRS (Disease Type)
- Emerging Opportunity Segment: Modified/Attenuated Live (Product) | Oral (Route of Administration) | Foot & Mouth Disease (Disease Type)
Market Growth Drivers and Industry Trends
Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption
The continued occurrence of african swine fever (ASF), porcine reproductive and respiratory syndrome (PRRS), and other infectious diseases is increasing the emphasis on preventive health management across commercial swine production. The swine vaccines market will be supported by greater adoption of vaccination programs as producers seek to reduce disease-related losses, protect herd productivity, and strengthen biosecurity practices. Outbreaks can disrupt production through animal mortality, reproductive problems, slower growth, and additional veterinary requirements, making preventive disease control an important component of farm management. Growing awareness of the economic and operational consequences of infectious disease outbreaks is encouraging producers to incorporate vaccination more systematically into herd health strategies.
Growing global pork consumption driving herd health management and preventive vaccination demand
Rising demand for pork is encouraging producers to maintain healthier and more productive herds to support consistent meat supply and efficient livestock operations. As pork production expands across major producing regions, the swine vaccines market will benefit from stronger emphasis on preventive healthcare practices that help producers manage disease risks across larger and more commercially intensive herds. Vaccination can form an important part of herd health programs by supporting disease prevention and reducing disruptions that can affect animal performance and production continuity. The increasing scale of pork production also places greater importance on coordinated veterinary management, disease monitoring, and preventive interventions throughout different stages of the production cycle.
Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency
Technological innovation in vaccine delivery and formulation is making herd immunization more practical for large-scale swine operations. For the swine vaccines market, the development of needle-free delivery systems can simplify vaccination procedures, reduce handling-related challenges, and support more efficient administration across commercial herds. At the same time, multivalent vaccines that provide protection against multiple relevant pathogens can help streamline herd health programs by reducing the need for separate vaccination interventions. These technologies can improve operational efficiency for producers while supporting more consistent implementation of preventive healthcare practices, particularly in intensive farming environments where labor management, animal handling, and disease control must be coordinated closely.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of ASF and PRRS outbreaks increasing swine vaccination program adoption | 1.90% | High | Asia Pacific, Europe | High | Near Term |
| Growing global pork consumption driving herd health management and preventive vaccination demand | 1.60% | Moderate | Asia Pacific, North America | High | Mid Term |
| Advancements in needle-free and multivalent vaccine technologies improving farm operational efficiency | 1.30% | Moderate | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of 40.77% in 2026 in the swine vaccines market, supported by well-developed livestock production systems, established veterinary healthcare infrastructure, and strong emphasis on herd health and disease prevention. Producers are increasingly prioritizing vaccination as part of comprehensive biosecurity strategies to reduce disease-related losses and maintain productivity. Veterinary research capabilities, structured animal-health programs, and greater adoption of preventive healthcare practices further contribute to the region’s strong market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, driven by expanding pork production, rising awareness of livestock disease management, and increasing efforts to strengthen animal-health practices. Growing commercial farming operations are encouraging producers to adopt preventive vaccination programs to protect herd productivity and improve production resilience. Investments in veterinary infrastructure, improvements in farm biosecurity, and increasing demand for reliable disease-control solutions are creating additional opportunities for vaccine adoption across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Disease ControlGermany focuses on preventive swine health management through targeted vaccination and strong veterinary monitoring. German livestock producers increasingly adopt vaccines alongside biosecurity measures to maintain herd productivity and support efficient disease control practices.
France 🇫🇷
Commercial Herd ResilienceFrance supports swine vaccine adoption through integrated herd health management and preventive veterinary practices. French producers increasingly combine vaccination with surveillance and farm management improvements to maintain stable livestock production and animal welfare standards.
Italy 🇮🇹
Farm Health ManagementItaly is expanding the use of swine vaccines as part of practical disease prevention strategies across commercial pig farms. Veterinary services in Italy are promoting vaccination schedules and biosecurity measures that strengthen herd health and improve production continuity.
Japan 🇯🇵
Biosecure Livestock ProtectionJapan emphasizes preventive vaccination supported by strict animal health standards and intensive disease monitoring. Swine producers in Japan continue adopting high-quality vaccines that fit integrated herd management strategies while minimizing disease-related production risks.
South Korea 🇰🇷
Veterinary Prevention StrategySouth Korea continues strengthening swine disease prevention through coordinated vaccination programs and enhanced livestock health management. Vaccine adoption in South Korea is supported by continuous monitoring, veterinary collaboration, and improved farm biosecurity practices.
United States 🇺🇸
Herd Health ProgramsThe U.S. prioritizes comprehensive swine vaccination strategies to improve herd health and reduce production losses from infectious diseases. Vaccine developers are supporting producers with advanced immunization programs, disease surveillance, and updated vaccine technologies for commercial operations.
Segment Leadership and Growth Trends
Swine Vaccines Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Inactivated (Killed) (Largest Segment) vs Modified/Attenuated Live (Fastest-Growing Segment)
The inactivated (killed) segment dominated the swine vaccines market with a 54.63% share in 2026, supported by its established use in swine health programs and its suitability for managing infectious disease risks across commercial pig production. These vaccines provide a well-established approach to disease prevention, with predictable handling and broad acceptance among producers and veterinary professionals. Growing emphasis on herd health, biosecurity, and reducing production losses from preventable diseases continues to sustain demand for inactivated vaccine formulations.
Modified/attenuated live vaccines are gaining momentum as swine producers increasingly seek effective immunization approaches that can support rapid and durable immune responses. Their ability to stimulate strong immune protection can make them valuable within disease-control programs where efficient herd protection is a priority. Increasing focus on preventive veterinary care, disease containment, and productivity preservation is encouraging greater consideration of live vaccine technologies, supporting their faster market expansion.
Route of Administration Segment Analysis: Injectables (Largest Segment) vs Oral (Fastest-Growing Segment)
Injectables held the largest share of the swine vaccines market at 72.76% in 2026, reflecting their established role in veterinary vaccination programs and their ability to deliver controlled vaccine doses directly into the animal. Injectable administration is widely integrated into structured herd-health protocols, allowing producers and veterinary teams to maintain systematic immunization practices. Its established infrastructure, familiarity among animal-health professionals, and suitability for targeted disease prevention continue to support its dominant position.
Oral administration is experiencing faster growth as producers seek vaccination approaches that can simplify handling and improve practicality across herd-management environments. Oral delivery can reduce the need for individual animal restraint, potentially making immunization more convenient in certain production settings. Growing interest in labor-efficient veterinary practices and less disruptive herd-management procedures is supporting greater attention toward oral vaccination technologies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Inactivated (Killed), Modified/Attenuated Live, Others | Inactivated (Killed) | Modified/Attenuated Live |
| Route of Administration | Injectables, Intranasal, Oral | Injectables | Oral |
| Disease Type | Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Others | PRRS | Foot & Mouth Disease |
Competitive Landscape and Market Positioning
Top players in the swine vaccines market:
1. Zoetis Inc. (United States)
2. Merck & Co. Inc. (United States)
3. Boehringer Ingelheim International GmbH (Germany)
4. Elanco Animal Health Incorporated (United States)
5. Ceva Santé Animale (France)
6. HIPRA S.A. (Spain)
7. Virbac S.A. (France)
8. Phibro Animal Health Corporation (United States)
9. Biogénesis Bagó S.A. (Argentina)
10. Indian Immunologicals Ltd. (India)
The swine vaccines market is witnessing heightened activity as producers focus on improving disease prevention and livestock productivity. Companies are expanding vaccine portfolios targeting emerging viral infections and region-specific disease outbreaks to strengthen their market reach. Increased collaboration with veterinary research institutions and rising investments in advanced vaccine delivery technologies are further supporting innovation and enhancing the effectiveness of immunization programs across commercial swine farming operations.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. (United States) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| Boehringer Ingelheim International GmbH (Germany) | |||||||
| Elanco Animal Health Incorporated (United States) | |||||||
| Ceva Santé Animale (France) | |||||||
| HIPRA S.A. (Spain) | |||||||
| Virbac S.A. (France) | |||||||
| Phibro Animal Health Corporation (United States) | |||||||
| Biogénesis Bagó S.A. (Argentina) | |||||||
| Indian Immunologicals Ltd. (India). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Boehringer Ingelheim | Sep-25 | Boehringer Ingelheim launched INGELVAC CIRCOFLEX AD in the U.S., the first single-dose swine vaccine combining PCV2a and PCV2d antigens. Designed for rapid onset of immunity and long-term protection, the vaccine addresses the rising prevalence of PCV2d strains, providing producers with an efficient tool to improve herd health and operational profitability. |
| European Medicines Agency | Jun-25 | The EMA issued a positive opinion for Biobhyo, a novel vaccine developed to prevent swine dysentery caused by Brachyspira hyodysenteriae. This regulatory milestone represents a significant advancement in controlling a major enteric disease, offering producers a targeted preventive solution to reduce reliance on antibiotics and enhance overall swine herd health. |
| Virbac | Apr-25 | Virbac launched a 2-in-1 swine vaccine in France targeting leptospirosis and porcine parvovirus in gilts and sows. By combining protection against two reproductive diseases into a single dose, the vaccine streamlines vaccination protocols, enhances immunization efficiency, and aligns with the company’s strategic focus on delivering integrated preventive health solutions to European producers. |
| Ceva Santé Animale | Oct-24 | Ceva Santé Animale received European marketing authorization for Cirbloc M Hyo, a combination vaccine protecting against Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae. The single-dose formulation provides extended coverage through the fattening period, reinforcing Ceva’s competitive position and commitment to simplifying respiratory health management for European swine producers. |
| Merck & Co., Inc. | Sep-24 | Merck Animal Health received marketing authorization from the EMA for PORCILIS PCV M Hyo ID, an intradermal vaccine for swine. This regulatory approval expands the company's portfolio of advanced immunization tools, providing a needle-free delivery option that enhances piglet welfare and simplifies respiratory disease management in intensive swine production systems. |
| Merck & Co., Inc. | Jun-23 | Merck Animal Health launched Circumvent CML, a first-of-its-kind 3-in-1 swine vaccine designed to protect against PCV-2a, PCV-2d, Mycoplasma hyopneumoniae, and Lawsonia intracellularis. By integrating multiple antigens into a single 2cc dose, the product significantly reduces labor requirements, handling stress, and the risk of application errors in swine production environments. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Swine Vaccines Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Farm Size | Small-Scale Farms, Medium-Scale Farms, Large-Scale Farms, Industrial-Scale Farms |
| Swine Production System | Farrow-to-Finish, Farrow-to-Wean, Nursery-to-Finish, Specialized Breeding Operations |
| Vaccination Program | Routine Preventive Vaccination, Outbreak-Driven Vaccination, Maternal Immunization, Targeted Herd Vaccination |
Swine Vaccines Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Global Swine Disease Risk Assessment |
|
| Livestock Health Management Transformation |
|
| Precision Livestock Integration Opportunities |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of swine vaccines?
What is the anticipated CAGR of the swine vaccines industry?
How are recurring ASF and PRRS outbreaks influencing vaccination procurement strategies in the swine vaccines market?
How are advancements in vaccine delivery technologies affecting operational efficiency in commercial swine farming?
Why do Inactivated (Killed) vaccines hold the largest share of the swine vaccines market?
Why is Oral administration the fastest-growing route in the swine vaccines market?
What factors make North America the leading swine vaccines market?
Why is demand for swine vaccines increasing in Asia Pacific?
Which organizations are considered leaders in the swine vaccines landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization